Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062285 | 0.95 | DRD4 (0.49) | TP53THRBDRD4MCHR1SIGMAR1 | |
| SCHEMBL12932875 | 0.92 | TP53 (0.61) | TP53THRBDRD4POLBMCHR1 | |
| SCHEMBL3427502 | 0.88 | HTR4 (0.42) | TP53POLBMCHR1SIGMAR1HTR4 | |
| SCHEMBL1060900 | 0.87 | SMN1; SMN2 (0.55) | TP53THRBDRD4MCHR1SIGMAR1 | |
| SCHEMBL10314470 | 0.87 | KCNH2 (0.41) | TP53THRBDRD4SIGMAR1HTR4 | |
| SCHEMBL10314451 | 0.87 | HRH1 (0.46) | TP53DRD4MCHR1SIGMAR1HTR4 | |
| Hydrochloric Acid SCHEMBL1061991 | 0.86 | HRH1 (0.45) | TP53DRD4MCHR1SIGMAR1HTR4 | |
| SCHEMBL12933491 | 0.86 | HTR4 (0.41) | TP53THRBPOLBMCHR1SIGMAR1 | |
| SCHEMBL10314471 | 0.85 | TP53 (0.42) | TP53POLBMCHR1HTR4 | |
| SCHEMBL10314472 | 0.85 | HTR4 (0.43) | TP53POLBMCHR1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399449-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | TP53 3556/4885THRB 469/4885DRD4 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.